Erratum to: Targeting NAD(P)H:Quinone Oxidoreductase (NQO1) in Pancreatic Cancer (10.1002/mc.20107);Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer

Molecular Carcinogenesis

Volumn 43, Issue 4, 2005, Pages 215-224

  Lewis, Anne M ^b   Ough, Matthew ^b   Hinkhouse, Marilyn M ^c   Tsao, Ming Sound ^d   Oberley, Larry W ^a   Cullen, Joseph J ^a,b,c,e  

^a Department of Surgery ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

NAD(P)H:quinone oxidoreductase; Pancreatic cancer; Streptonigrin; Tissue microarray; pancreatic cancer; antioxidants; streptonigrin

Indexed keywords

DICOUMAROL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RUFOCROMOMYCIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; COLON MUCOSA; CONTROLLED STUDY; DETOXIFICATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OXIDATION REDUCTION REACTION; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN TARGETING; WESTERN BLOTTING;

EID: 23644443066     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20199     Document Type: Erratum

References (50)

1. Powis G, Svingen BA, Appel P. Quinone-stimulated superoxide formation by subcellular fractions, isolated hepatocytes, and other cells. Mol Pharmacol 1981;20:387-394.
2. Chesis PL, Levin DE, Smith MT, Ernster L, Ames BN. Mutagenicity of quinones: Pathways of metabolic activation and detoxification. Proc Natl Acad Sci USA 1984;81:1696-1700.
3. Lind C, Hochstein P, Ernster L. DT-Diaphorase as a quinone reductase: A cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 1982; 216:178-185.
4. Thor H, Smith MT, Hartxell P, Bellomo G, Jewell SA, Orrenius S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implication of oxidative stress in intact cells. J Biol Chem 1982;257: 12419-12425.
5. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000;29:246-353.
6. Huggins C, Fukunishi R. Induced protection of adrenal cortex against 7, 12-dimethylbenz(alpha)anthracene:influence of ethionine:induction of menadione reductase:incorporation of thymidine H3. J Exp Med 1964;119:923-942.
7. Strassburg A, Strassburg CP, Manns MP, Tukey RH. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol 2002;61: 320-325.
8. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63:2649-2657.
9. Lewis A, Ough M, Li L, et al. Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. Clin Can Res 2004;10:4550-4558.
10. Cone R, Hasan SK, Lown JW, Morgan AR. The mechanism of the degradation of DNA by streptonigrin. Can J Biochem 1976;54:219-223.
11. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao M-S. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts by transfection with the E6E7 gene of human papilloma virus 16. Am J Pathol 1996;148:1763-1770.
12. Ouyang H, Mou L-J, Luk C, Liu N, Squire J, Tsao M-S. Paradiploid human pancreatic duct epithelial cell lines with near normal phenotype. Am J Pathol 2000;157:1623-1631.
13. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasm: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-586.
14. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-2972.
15. Af-Aynati MM, Radulovich N, Riddell RH, Tsao MS. Epithelial-cadherin and β-catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res 2004;10:1235-1240.
16. Lam EWN, Hammad HM, Zwack R, et al. Immunolocalization and adenoviral vector-mediated manganese superoxide dismutase gene transfer to experimental oral tumors. J Dent Res 2000;79:1410-1417.
17. Belinsky M, Jaiswal AK. NADPH:quinone oxidoreductasel (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993;12:103-117.
18. Trush MA, Twerdok LE, Rembish SJ, Zhu H, Li YB. Analysis of target cell susceptibility as a basis for the development of a chemoprotective strategy against benzene-induced hematotoxicities. Envrion Health Perspect 1996;104:1227-1234.
19. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. J Biol Chem 2000;275:5416-5424.
20. Llopis J, Ernster L, Cadenas E. Effect of glutathione on the redox transitions of naphthohydroquinone derivatives formed during DT-diaphorase catalysis. Free Radic Res Commun 1990;8:271-285.
21. Buettner GR. The pecking order of free radicals and antioxidants: Lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 1993;300:535-543.
22. Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT, Gibson NW. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev 1993;12:83-101.
23. Ross D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 1994;6:493-500.
24. Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 1995;49:127-140.
25. Siegel D, Beall H, Senekowitsch C, et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992;31:7879-7885.
26. Siegel D, Givson NW, Preusch PC, Ross D. Metabolism of diaziquone by NAD(P)H(quinone acceptor) oxidoreductase (DT-diaphorase): Role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990;50:7293-7300.
27. Radjendirane V, Joseph P, Lee YH, et al. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadionetoxicity. J Biol Chem 1998;273:7382-7389.
28. Brar SS, Kennedy TP, Whorton AR, et al. Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-B in malignant melanoma cells. Am J Physiol 2001;280:C659-C676.
29. Winski SL, Swann E, Hargreaves RHJ, et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinines. Biochem Pharm 2001;61:1509-1516.
30. Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler F, Ross D. Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones:quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 1995;48:499-504.
31. Rao KV, Biemann K, Woodward RB. The structure of streptonigrin. J Am Chem Soc 1963;85:2532-2533.
32. Oleson JJ, Calderella LA, Mjos KJ, Reith AR, Thie RS, Toplin I. The effects of streptonigrin on experimental tumors. Antiblot Chemother 1961;11:158-164.
33. Reilly HC, Sigiura K. An antitumor spectrum of streptonigrin. Antibiot Chemother 1961;11:174-177.
34. Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW, Ross D. Metabolism of bioreductive antitumor compounds. Cancer Res 1994;54:3196-3201.
35. Mizuno NS. Effects of streptonigrin on nucleic acid metabolism of tissue culture cells. Biochem Biophys Acta 1965;108: 394-403.
36. Levine M, Borthwick M. The action of streptonigrin on bacterial DNA metabolism and on induction of phage production in lysogenic bacteria. Virology 1963;21:568-574.
37. White HL, White JR. Lethal action and metabolic effects of streptonigrin on Escherichia coli. Mol Pharmacol 1968;4: 549-565.
38. Lown JW, Sim SK. Studies related to anti-tumor antibiotics. Part VIII. Cleavage of DNA by streptonigrin analogues and the relationship to antineoplastic activity. Can J Biochem 1976: 54:446-452.
39. Beall HD, Liu Y, Siegel D, Bolton EM, Gibson NW, Ross D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharm 1996;51:645-652.
40. Dinkova-Kostova AT, Talalay P. Persuasive evidence that quinone reductase type 1 (DT-Diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radic Biol Med 2000;29:231-240.
41. Cullen JJ, Hinkhouse MM, Grady M, et al. Dicumarol inhibition of NAD(P)H:quinine oxidoreductase (NQO1) induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res 2003;63:5513-5520.
42. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study. Br J Surg 1995; 82:111-115.
43. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
44. Yeo CJ, Cameron JL. Pancreatic cancer. Curr Probl Surg 1999;36:59-152.
45. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68-72.
46. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas: Is it really improving? Ann Surg 1995;221:59-66.
47. Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson ANA. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999; 126:178-183.
48. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: A report of treatment and survival trends for 100 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
49. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
50. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350: 1200-1210.